Loading…
Catalyst Pharmaceuticals, Inc. is projected to rise to $41.17 by 2027, a +31% move from its current price of $31.32. CPRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $30.84 | $31.34 | $31.84 | +0.06% |
| May 30 | $30.66 | $31.36 | $32.07 | +0.13% |
| May 31 | $30.53 | $31.38 | $32.26 | +0.19% |
| Jun 1 | $30.41 | $31.40 | $32.42 | +0.25% |
| Jun 2 | $30.32 | $31.42 | $32.56 | +0.31% |
| Jun 3 | $30.24 | $31.44 | $32.69 | +0.38% |
| Jun 4 | $30.16 | $31.46 | $32.81 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.16 | $31.46 | $32.81 | +0.44% |
| Week 2 | $29.77 | $31.60 | $33.54 | +0.88% |
| Week 3 | $29.50 | $31.74 | $34.14 | +1.33% |
| Week 4 | $29.30 | $31.88 | $34.68 | +1.78% |
| Week 5 | $29.14 | $32.02 | $35.18 | +2.22% |
| Week 6 | $29.00 | $32.16 | $35.65 | +2.68% |
| Week 7 | $28.89 | $32.30 | $36.11 | +3.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Catalyst Pharmaceuticals, Inc. is a healthcare company described as a commercial-stage biopharmaceutical company focusing on developing and commercializing medicines for patients living with rare diseases in the United States.
It offers Firdapse for lambert-eaton myasthenic syndrome (LEMS); Fycompa for focal onset seizures and tonic-clonic seizures; and AGAMREE, a corticosteroid for Duchenne muscular dystrophy.
The company was founded in 2002 and is based in Coral Gables, Florida. It has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
Catalyst Pharmaceuticals, Inc. (CPRX) is a healthcare stock currently trading at $31.26 per share, with a market cap of $3.83B, and it is ranked 1541.
The price forecast envisions a rising path over the coming years, with 2026 average price $31.26, 2027 $41.54, 2028 $50.54, 2029 $61.30, 2030 $79.51, 2031 $91.53, 2032 $103.37, 2033 $116.55, 2034 $123.32, 2035 $140.78, 2040 $251.53, and 2050 $574.08.
Max values rise from $41.59 in 2026 to $939.43 in 2050, while min values rise from $22.33 in 2026 to $379.80 in 2050. The forecast shows rising ROI from 0% in 2026 to 32.9% in 2027, 61.7% in 2028, 96.1% in 2029, 154.4% in 2030, 192.8% in 2031, 230.7% in 2032, 272.8% in 2033, 294.5% in 2034, 350.4% in 2035, 704.6% in 2040, and 1736.5% in 2050, with a bullish sentiment from 2027 onward.
A major floor 28.7% below — a decisive break under it would weaken the trend.
The nearest floor, 18.1% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 12.1% above — clearing it would confirm fresh momentum.
Key CPRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CPRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $31.29 | Buy | $31.28 | Buy |
| MA 10 | $31.24 | Buy | $31.12 | Buy |
| MA 20 | $30.62 | Buy | $30.37 | Buy |
| MA 50 | $27.33 | Buy | $28.26 | Buy |
| MA 100 | $25.62 | Buy | $26.41 | Buy |
| MA 200 | $23.55 | Buy | $24.68 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 73.64 | Sell |
| Stoch RSI (14) | 68.91 | Neutral |
| CCI (20) | 54.62 | Neutral |
| Williams %R (14) | -5.26 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | 0.55 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 94.74 | Sell |
| TRIX (15) | 0.70 | Buy |
| Awesome (5,34) | 2.35 | Buy |
| Ultimate (7,14,28) | 82.18 | Sell |
| Momentum (10) | 0.18 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 31.33 | Sell |
| ADX (14) | 40.45 | Buy |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is bullish, with RSI14 at 70. The stock’s moving averages place the price context as SMA50 at $27.00 and SMA200 at $23.44.
Support is listed at $25.34 and resistance at $31.28, while the 30-day price range is $27.95 to $34.96. This setup suggests potential near-term upside if momentum remains positive.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.33 | $31.32 | $41.67 | 0% | Neutral | |
| $33.64 | $41.17 | $52.75 | +31% | Bullish | |
| $40.20 | $50.10 | $65.88 | +60% | Bullish | |
| $48.15 | $60.93 | $81.78 | +95% | Bullish | |
| $61.13 | $78.38 | $107.06 | +150% | Bullish | |
| $69.66 | $90.40 | $125.40 | +189% | Bullish | |
| $78.01 | $102.36 | $143.99 | +227% | Bullish | |
| $86.36 | $114.50 | $163.13 | +266% | Bullish | |
| $90.93 | $121.76 | $175.52 | +289% | Bullish | |
| $102.63 | $138.71 | $202.17 | +343% | Bullish | |
| $175.28 | $247.05 | $377.23 | +689% | Bullish | |
| $371.71 | $561.82 | $919.28 | +16.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $22.33 | $31.32 | $36.63 | +0.00% |
| June 2026 | $27.38 | $31.94 | $37.98 | +1.96% |
| July 2026 | $28.27 | $33.17 | $39.82 | +3.86% |
| August 2026 | $28.27 | $33.32 | $40.29 | +0.45% |
| September 2026 | $27.97 | $33.09 | $40.25 | -0.68% |
| October 2026 | $28.49 | $33.82 | $41.36 | +2.21% |
| November 2026 | $28.81 | $34.30 | $42.15 | +1.42% |
| December 2026 | $28.28 | $33.76 | $41.67 | -1.58% |
Click any year to see its month-by-month CPRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CPRX could reach as high as $41.67, with a base case around $31.32 and support toward $22.33 — roughly 0% from $31.32. Price action looks broadly range-bound.
Expect CPRX to range from $33.64 to $52.75 through 2027. The $41.17 average target implies a +31% move from current prices. That is up +31% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The CPRX price prediction for 2028 points to an average of $50.10 (low $40.20, high $65.88) — a potential gain of +60% on today's $31.32. Momentum favours further upside here.
In 2029, CPRX is projected to trade between $48.15 and $81.78, averaging $60.93 — a potential gain of +95% from today's $31.32. That is up +22% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Catalyst Pharmaceuticals, Inc.'s 2030 outlook centres on $78.38, within a $61.13 to $107.06 range. That is up +29% on the projected 2029 average. That marks a +150% change versus current levels. Momentum favours further upside here.
By 2031, CPRX could reach as high as $125.40, with a base case around $90.40 and support toward $69.66 — roughly +189% from $31.32. Buyers look set to stay in control over this stretch.
Expect CPRX to range from $78.01 to $143.99 through 2032. The $102.36 average target implies a +227% move from current prices. That is up +13% on the projected 2031 average. Momentum favours further upside here.
The CPRX price prediction for 2033 points to an average of $114.50 (low $86.36, high $163.13) — a potential gain of +266% on today's $31.32. Buyers look set to stay in control over this stretch.
In 2034, CPRX is projected to trade between $90.93 and $175.52, averaging $121.76 — a potential gain of +289% from today's $31.32. That is up +6% on the projected 2033 average. Momentum favours further upside here.
Catalyst Pharmaceuticals, Inc.'s 2035 outlook centres on $138.71, within a $102.63 to $202.17 range. That is up +14% on the projected 2034 average. That marks a +343% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CPRX could reach as high as $377.23, with a base case around $247.05 and support toward $175.28 — roughly +689% from $31.32. Momentum favours further upside here.
Expect CPRX to range from $371.71 to $919.28 through 2050. The $561.82 average target implies a +16.9x move from current prices. That is up +127% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CPRX today (≈ 31.92848 CPRX) could be worth
$17,937.91
+$16,937.91 (+1694%) by 2050 · US Dollar
Based on the average projected CPRX price of $561.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CPRXwould be worth at today's price.
$1,000 invested in CPRX on May 27, 2025 (≈ 40.257649 CPRX) would be worth
$1,260.87
+$260.87 (+26.1%) today · 1.26× · US Dollar
Based on a CPRX entry price of $24.84 vs. today's $31.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.25 | $1,002.24 | +0.2% |
| 1 month ago | $29.27 | $1,070.04 | +7.0% |
| 3 months ago | $24.88 | $1,258.84 | +25.9% |
| 6 months ago | $23.41 | $1,337.89 | +33.8% |
| 1 year ago | $24.84 | $1,260.87 | +26.1% |
| All time (5.0y) ago | $5.53 | $5,663.65 | +466.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CPRX forecast.
Our base-case forecast reaches $63.00 around 2030.
Implied market cap at $63.00: $7.71B
The multi-year forecast shows a bullish trajectory, with the 2026 average price of $31.26 climbing to a 2050 average of $574.08.
Notable milestones include a 2030 average of $79.51 (ROI 154.4%), a 2040 average of $251.53 (ROI 704.6%), and a 2050 average of $574.08 (ROI 1736.5%). The sentiment is labeled BULLISH across 2027 through 2050, indicating a sustained optimistic view, though these are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast shows an avg price of $79.51 in 2030, with a min of $62.00 and a max of $108.63; ROI 154.4%.
The forecast portrays a bullish path from 2027 onward with rising averages and positive sentiment, but these are estimates and not guarantees.
Yes. The forecast max in 2030 is $108.63 and in 2031 is $126.99, indicating a potential to exceed $100 in the forecast horizon.
Current price is $31.26 and market cap is $3.83B.
The 30-day technical picture is bullish with RSI14 at 70, SMA50 at $27.00, SMA200 at $23.44, support at $25.34, resistance at $31.28, and a 30-day range of $27.95–$34.96.
Catalyst Pharmaceuticals, Inc. Community Discussion
0Share your Catalyst Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.